[111In] Panitumumab

[111In]帕尼单抗

Report date: 2025/09/24 16:01:06

Base Information

Drug Name[111In] Panitumumab

Drug Alias Name111I-n panitumumab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive diagnostic agent +[4]

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesStanford University

China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute

Inactive CompaniesStanford University

Active IndicationsSquamous Cell Carcinoma of Head and Neck

Inactive IndicationsHead and Neck Neoplasms

Other Information

ATC CodeN/A